- Home
- NXP vs SYRE Comparison
NXP vs SYRE Comparison
Compare NXP & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXP
- SYRE
- Stock Information
- Founded
- NXP 1992
- SYRE 2013
- Country
- NXP United States
- SYRE United States
- Employees
- NXP N/A
- SYRE N/A
- Industry
- NXP Trusts Except Educational Religious and Charitable
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- NXP Finance
- SYRE Health Care
- Exchange
- NXP Nasdaq
- SYRE Nasdaq
- Market Cap
- NXP 730.9M
- SYRE 841.4M
- IPO Year
- NXP N/A
- SYRE 2016
- Fundamental
- Price
- NXP $14.08
- SYRE $16.57
- Analyst Decision
- NXP
- SYRE Buy
- Analyst Count
- NXP 0
- SYRE 6
- Target Price
- NXP N/A
- SYRE $55.00
- AVG Volume (30 Days)
- NXP 70.0K
- SYRE 469.1K
- Earning Date
- NXP 01-01-0001
- SYRE 05-08-2025
- Dividend Yield
- NXP 4.04%
- SYRE N/A
- EPS Growth
- NXP N/A
- SYRE N/A
- EPS
- NXP 0.54
- SYRE N/A
- Revenue
- NXP N/A
- SYRE N/A
- Revenue This Year
- NXP N/A
- SYRE N/A
- Revenue Next Year
- NXP N/A
- SYRE N/A
- P/E Ratio
- NXP $26.81
- SYRE N/A
- Revenue Growth
- NXP N/A
- SYRE N/A
- 52 Week Low
- NXP $12.91
- SYRE $10.91
- 52 Week High
- NXP $14.89
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- NXP 52.00
- SYRE 63.04
- Support Level
- NXP $13.94
- SYRE $14.75
- Resistance Level
- NXP $14.15
- SYRE $15.71
- Average True Range (ATR)
- NXP 0.12
- SYRE 0.76
- MACD
- NXP 0.00
- SYRE 0.18
- Stochastic Oscillator
- NXP 63.24
- SYRE 94.23
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a diversified closed-end investment company. It seeks to provide current income and stable dividends, exempt from regular federal and designated state income taxes, consistent with the preservation of capital by investing primarily in a portfolio of municipal obligations.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.